NewGenIvf Group is a Bangkok-based fertility-clinic operator that used a de-SPAC listing to become a serial issuer of convertibles, reverse splits, and side bets, while the actual clinics shrank. The investment debate is not whether Asia wants IVF. It is whether a three-clinic cash engine can fund a holding company that now talks about prediction-market equity, Ras Al Khaimah property, and tokenized assets, after eight reverse splits and a year of going-concern language. The market already answers with a sub-$2 million capitalization, which treats the claimed book value as mostly un-monetized appraisal rather than cash.
Fiscal 2025 revenue slipped to just under $5 million. Reported net income near $10 million came almost entirely from bargain-purchase gains on MicroSort and Nodexus, not from treating more patients. Year-end cash was under $1 million against several million of convertible paper that was later exchanged into a larger senior note. That is the opposite of a transformation that pays for itself. It is a listed vehicle using accounting gains and fresh paper to stay public while the operating line contracts.
The next several months resolve three questions. Does clinic cash cover corporate overhead without another primary sale. Does the latest reverse split keep the bid above the exchange floor long enough to avoid another consolidation. And does any of the K25.ai or cytometry story produce cash, or only more shares. If the clinics keep shrinking while notes and a best-efforts registration sit over a thin Class A count, the residual claim stays a listing stub.